NBRV News and Press, Nabriva Therapeutics plc From 05/29/20

If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe   CHMP opinion supported by robust safety and efficacy data from two global pivotal Phase 3 trials of XENLETA ...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Nabriva Therapeutics' (NASDAQ: NBRV ) Xenleta (lefamulin) for the treatment of community-acquired pneumonia in adults. More news on: Nabriva Therapeutics plc, Healthcare stocks new...

DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer ...

DUBLIN, Ireland, May 18, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the publication of a study entitled, A Multic...

The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2020 Q1 earnings Read more ...

Nabriva Therapeutics Plc (NBRV) Q1 2020 Earnings Conference Call May 11, 2020 16:30 ET Company Participants Gary Sender - Chief Financial Officer Ted Schroeder - Chief Executive Officer Jennifer Schranz - Chief Medical Officer Francesco Maria Lavino - Chief Commercial Officer ...

Nabriva Therapeutics (NASDAQ: NBRV ): Q1 GAAP EPS of -$0.25 beats by $0.02 . More news on: Nabriva Therapeutics plc, Earnings news and commentary, Healthcare stocks news, , Read more ...

-Cash runway extended into the fourth quarter of 2020 through judicious resource management- - XENLETA managed care coverage and patient reimbursement continues to strengthen- -Potential value-creating life cycle management for XENLETA initiated via non-dilutive support- -Confe...

DUBLIN, Ireland, May 11, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer ...

DUBLIN, Ireland, May 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter fina...